Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

Basch, Ethan; Loblaw, D.A.; Oliver, Thomas K.; Carducci, Michael A.; Chen, I‐Chun; Frame, James N.; Garrels, Kristina; Hotte, Sébastien J.; Kattan, Michael W.; Raghavan, Derek; Saad, Fred; Taplin, Mary Ellen; Walker-Dilks, Cindy; Williams, J. Koudy; Winquist, Eric; Bennett, Charles L.; Ted, Wootton,; Rumble, R. Bryan; Dusetzina, Stacie B.; Virgo, Katherine S.

doi:10.1200/jco.2013.54.8404

Cited by 202 publications

(140 citation statements)

References 50 publications

(18 reference statements)

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Most CRPC patients have metastases at diagnosis or develop widespread disease during the first 2 years of follow-up. First-line chemotherapeutic agents such as docetaxel, and second-line chemotherapy with cabazitaxel, are often toxic and prolong life by only a few months (2). Postchemotherapy androgen deprivation therapy with abiraterone acetate and enzalutamide has been shown to prolong overall survival by only 3.9 and 4.8 mo, respectively, compared with placebo.…”

mentioning

confidence: 99%

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013

et al. 2016

View full text Add to dashboard Cite

A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68 Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177 Lu-PSMA ligands. 68 Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.

show abstract

mentioning

confidence: 99%

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013

et al. 2016

View full text Add to dashboard Cite

show abstract

“…According to the American Society of Clinical Oncology and the Cancer Care Ontario clinical practice guideline, the main option for patients with metastatic CRPC is systemic therapy with docetaxel, with moderate benefit, which is however supported by strong evidence (7). Additionally, the guideline suggests continuation of androgen deprivation indefinitely (7).…”

Section: Discussionmentioning

confidence: 99%

Neuroendocrine differentiation in castration-resistant prostate cancer: A case report

Priftakis

Kritikos

Stavrinides

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The most common type of prostate cancer is acinar adenocarcinoma, which is androgen-dependent and, therefore, treated with chemical or surgical castration and androgen receptor inhibition. However, the disease usually progresses to castration-resistant prostate cancer (CRPC). A neuroendocrine pattern is frequently observed in the cellular composition of CRPC, which is considered to emerge as an effect of androgen deprivation therapy. This is the case report of a 69-year-old patient with prostate adenocarcinoma, who, after an initial period of disease control with radiotherapy and antiandrogens, was diagnosed with CRPC with high levels of prostate-specific antigen (PSA), unresponsive to androgen inhibition, with accompanying lung and osseous metastases. Bronchial biopsy of the lung metastasis revealed infiltration by non-small-cell adenocarcinoma of prostatic origin with neuroendocrine characteristics. On somatostatin receptor scintigraphy with 99m Tc-octreotide, there was high uptake by almost all known lung and osseous metastases. The patient was subsequently treated with a combination of docetaxel and octreotide, and a partial response was observed 6 months later, with reduction of the PSA level and the size of the lung metastasis. The aim of the present study was to provide a clinical example of the previously demonstrated, in vitro and in vivo, synergistic antitumor activities of docetaxel and octreotide in cases of CRPC selected by means of histological confirmation of their neuroendocrine nature and somatostatin receptor scintigraphy.

show abstract

“…In the 2014 version of the European Association of Urology guidelines, DOC may be the treatment of choice for all patients with metastatic CRPC, excluding patients with with a performance status >2 (12). In the 2014 version of the American Society of Clinical Oncology guidelines, Basch et al suggested DOC and prednisone should be offered, but this type of therapy should be discussed with patients at the time of decision-making in relation to the apparently lower risk associated with other options and to the patient's individual circumstances (13). Pre-DOC therapy against CRPC with abiraterone acetate (14) and enzalutamide (15) demonstrated survival and quality-of-life benefits.…”

Section: Discussionmentioning

confidence: 99%

Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer

Nakano

Shoji

Higure

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The objective of this study was to report our experience with weekly low-dose docetaxel (DOC) chemotherapy for patients with castration-resistant prostate cancer (CRPC). From 2007 to 2014, 39 consecutive patients received weekly low-dose DOC; the oncological effectiveness, side effects and tolerability were prospectively analyzed. The median patient age, serum prostate-specific antigen (PSA) level and Gleason score at diagnosis of prostate cancer were 71 years (range, 55-83 years), 187 ng̸ml (range, 2.0-1711 ng̸ml) and 8 (range, 5-10), respectively. The median number of cycles of DOC was 7 (range, 1-45 cycles). Of the 39 patients, the PSA level decreased by >50% in 13 (33%). In the multivariate analysis of prediction of patient overall survival, a decrease of the PSA level to <50% was a significant predictor (hazard ratio = 6.913; 95% confidence interval: 1.147-41.669; P=0.035). The median cancer-specific overall survival from the diagnosis of CRPC was 16.7 months (range, 2-54 months). Grade 3 toxicities were observed in 5 patients (13%); specifically, limb edema, nausea and hepatic disorders were detected in 2 (5%), 2 (5%) and 1 patient (3%), respectively. Treatment-related death (grade 5) occurred in 1 patient due to interstitial pneumonia after two courses of chemotherapy. The chemotherapy was completed in the majority of the patients (n=37, 94.8%) in the outpatient department, without interruption. These findings suggest that weekly low-dose DOC is feasible and safe for selected patients with CRPC, without treament with novel agents, such as abiraterone, enzalutamide and cabazitaxel.

show abstract

Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

Cited by 202 publications

References 50 publications

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013

Neuroendocrine differentiation in castration-resistant prostate cancer: A case report

Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer

Contact Info

Product

Resources

About